Latest News and Press Releases

New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen...

New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...

CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...

VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) applauds the Australian Therapeutic Goods Administration (TGA) in allowing for...

AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...

Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...

NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...

Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...

Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary...

First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...